Advanced

AJNR - American Journal of Neuroradiology

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Ceyssens, S. Articles by Mortelmans, L. Search for Related Content PubMed PubMed Citation Articles by Ceyssens, S. Articles by Mortelmans, L.

American Journal of Neuroradiology 27:1432-1437, August 2006
© 2006 American Society of Neuroradiology

BRAIN

[¹¹C]Methionine PET, Histopathology, and Survival in Primary Brain Tumors and Recurrence

S. Ceyssens^a, K. Van Laere^a, T. de Groot^b, J. Goffin^c, G. Bormans^b and L. Mortelmans^a

^a Division of Nuclear Medicine, University Hospital Leuven, Leuven, Belgium
^b Laboratory of Radiopharmaceutical Chemistry, University Hospital Leuven, Leuven, Belgium
^c Department of Neurosurgery, University Hospital Leuven, Leuven, Belgium

Address correspondence to Koen Van Laere, MD, PhD, DrSc, Division of Nuclear Medicine, University Hospital Leuven, Herestraat 49, 3000 Leuven, Belgium; e-mail: koen.vanlaere{at}uz.kuleuven.ac.be

BACKGROUND AND PURPOSE: [¹¹C]Methionine (MET) PET imaging is a sensitive technique for visualizing primary brain tumors and recurrence/progression after therapy. The aim of this study was to evaluate the relationship between the uptake of MET and histopathologic grading and to investigate the prognostic value of the tracer, in both settings.

METHODS: Cerebral uptake of MET was determined in 52 patients: in 26 patients for primary staging (group A) and 26 patients with suspected brain tumor recurrence/progression after therapy (group B). Semiquantitative methionine uptake indices (UI) defined by the tumor (maximum)-to-background ratio was correlated with tumor grade and final outcome.

RESULTS: Overall median survival was 34.9 months. MET showed pathologically increased uptake in 41 of 52 scans. Although a weak linear correlation between MET uptake and grading was observed (R = 0.38, P = .028), analysis of variance showed no significant differences in MET UI between tumor grades for either group A or B. Benign and grade I lesions showed significant difference in MET uptake in comparison with higher grade lesions (P = .006). Using Kaplan-Meier survival analysis, no thresholds could be found at which MET was predictive for survival. Proportional hazard regression showed that only WHO grading class (low versus high) was predictive of survival (P = .015).

CONCLUSION: Interindividual MET uptake variability does not allow noninvasive grading on an individual patient basis. Moreover, there is no significant prognostic value in studying maximal methionine UI in brain tumors. The clinical use of MET should therefore be primarily focused on questions such as detection of recurrence, biopsy guidance, and radiation therapy target volume delineation.

This article has been cited by other articles:

				C. Plathow and W. A. Weber Tumor Cell Metabolism Imaging J. Nucl. Med., June 1, 2008; 49(Suppl_2): 43S - 63S. [Abstract] [Full Text] [PDF]